Accumulation of KRM-1648 by Mycobacterium aurum and Mycobacterium tuberculosis

被引:5
|
作者
Piddock, LJV [1 ]
Ricci, V [1 ]
机构
[1] Univ Birmingham, Sch Med, Antimicrobial Agents Res Grp, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England
关键词
D O I
10.1093/jac/45.5.681
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
After exposure to 2 mg/L C-14-labelled KRM-1648 (a new broad-spectrum benzoxazinorifamycin antibiotic) for 5 min, a steady-state concentration of 31.3 +/- 3 ng/mg cells KRM-1648 and 12.6 +/- 0.3 ng/mg cells KRM-1648 was accumulated by wild-type antibiotic-susceptible Mycobacterium aurum (A+) and Mycobacterium tuberculosis (H37Rv), respectively. However, 2 mg/L KRM-1648 was bactericidal for M. tuberculosis. A steady-state concentration of 3.7 +/- 0.1 ng/mg cells KRM-1648 was accumulated after exposure to 0.5 mg/L. At pH 4 higher concentrations were accumulated than at pH 7. A sub-inhibitory concentration of ethambutol increased the concentration of KRM-1648 accumulated, but Tween 80 and reserpine had little or no effect.
引用
收藏
页码:681 / 684
页数:4
相关论文
共 50 条
  • [1] Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model
    Klemens, SP
    Cynamon, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) : 298 - 301
  • [2] Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages
    Mor, N
    Simon, B
    Heifets, L
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1482 - 1485
  • [3] ACTIVITY OF KRM-1648, A NEW BENZOXAZINORIFAMYCIN, AGAINST MYCOBACTERIUM-TUBERCULOSIS IN A MURINE MODEL
    KLEMENS, SP
    GROSSI, MA
    CYNAMON, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) : 2245 - 2248
  • [4] Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages
    Bermudez, LE
    Inderlied, CB
    [J]. MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1997, 3 (03): : 277 - 282
  • [5] In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin -: Anti-mycobacterial activity of KRM-1648
    Dhople, AM
    [J]. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2001, 51 (06): : 501 - 505
  • [6] IN-VITRO AND IN-VIVO ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST MYCOBACTERIUM-TUBERCULOSIS
    HIRATA, T
    SAITO, H
    TOMIOKA, H
    SATO, K
    JIDOI, J
    HOSOE, K
    HIDAKA, T
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) : 2295 - 2303
  • [7] Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis
    Yang, B
    Koga, H
    Ohno, H
    Ogawa, K
    Fukuda, M
    Hirakata, Y
    Maesaki, S
    Tomono, K
    Tashiro, T
    Kohno, S
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (05) : 621 - 628
  • [8] Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis
    Piddock, LJV
    Williams, KJ
    Ricci, V
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) : 159 - 165
  • [9] In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis
    Yamamoto, T
    Amitani, R
    Suzuki, K
    Tanaka, E
    Murayama, T
    Kuze, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) : 426 - 428
  • [10] Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis
    Park, YK
    Kim, BJ
    Ryu, S
    Kook, YH
    Choe, YK
    Bai, GH
    Kim, SJ
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2002, 6 (02) : 166 - 170